Best Peptides and Supplements for Mitochondrial Health: An Honest Evidence Ladder (2026)

The honest "best for mitochondrial health" answer is not a peptide at all: the compounds with the strongest human evidence are supplements, led by Urolithin A, creatine, CoQ10, and the NAD+ precursor NR, while the mitochondrial peptides everyone is excited about are still animal-stage. This page answers the real question two ways at once: where each compound sits on an evidence ladder, and what our own peptide community actually tracks for energy and mitochondrial goals.

Most "best for mitochondria" lists pick a lane. Supplement blogs rank CoQ10 and NMN; peptide vendors rank MOTS-c and SS-31; nobody puts supplements, peptides, and research chemicals on one honest ladder with a safety flag beside each. We do that here. The headline answer below is an evidence-tier ladder spanning the whole landscape, from strong human data to outright dangerous. Our first-party usage data is the secondary panel, because the supplement boom that drives this category sits mostly outside our peptide tracking. This page owns the narrow cellular-energy question; the broader anti-aging picture, including compounds like the bioregulator Epitalon, the heart peptide Cardiogen, and the metabolic fragment AOD-9604, lives on our best peptides for longevity pillar. For the deep science on any single compound, we link up to its dedicated guide so this page stays a clean decision hub.

Key Takeaways

• The honest best-for shortlist is evidence-led, in order: Urolithin A, creatine, CoQ10/ubiquinol, NR, NMN, then elamipretide (SS-31, prescription, rare-disease only). These have the most human data, and most are supplements, not peptides.
• The strongest human evidence is for supplements, not peptides. Urolithin A (mitophagy), creatine (ATP buffering), CoQ10 (electron-transport cofactor), and NR (NAD+ precursor) each have randomized human trials; the tracked peptides do not yet.
• NAD+ is the engine of the boom. Its precursors NR and NMN reliably raise blood NAD+ (NR by up to +142% at 1,000 mg in a 2019 RCT), but raising NAD+ is not the same as proven anti-aging, and human hard-endpoint benefits are still thin.
• One mitochondria drug is FDA-approved, for one rare disease. Elamipretide (SS-31, FORZINITY) was approved in September 2025 for Barth syndrome only. It is the pharma proof-of-concept, not a general energy supplement.
• "Ones to watch" (animal-only): MOTS-c and Humanin, the mitochondrial-derived peptides our community tracks, have strong animal data and recruiting human trials but no completed human efficacy RCT.
• Avoid or treat as dangerous: SLU-PP-332 and 5-amino-1MQ (animal-only), Cardarine (WADA-banned, rodent carcinogen), DNP (illegal, lethal), and unproven IV NAD+ and methylene blue energy claims.
• What our community tracks is not what is proven. Among the 4 tracked compounds, NAD+ leads at 32 percent, but the broader supplement boom (Urolithin A, NR, NMN, CoQ10, creatine) sits outside our peptide-tracking data.

What are the best compounds for mitochondrial health, by evidence?

Ranked by human evidence, the best-supported mitochondrial compounds are Urolithin A, creatine, CoQ10, NR, and NMN (all supplements), with elamipretide the only FDA-approved mito drug; the popular mitochondrial peptides (MOTS-c, Humanin) and research chemicals (SLU-PP-332, 5-amino-1MQ) are animal-only, and a few are outright dangerous. This is an evidence ladder, not a usage chart, and it is the real answer to the question.

The ladder below is the signature of this page. It places every serious candidate on a single axis from strong human evidence down to preclinical hype and danger, with a flag column that no competitor combines. The pattern it reveals is the whole story: the compounds with the best human data are mostly inexpensive supplements, the pharma frontier is a single rare-disease drug, and the gray-market peptides that dominate forum hype still have no human efficacy trial finished. Read the ladder first, then use the rest of the page to go deeper on whichever rung matters to you.

The evidence tiers are simple. Strong-human means multiple randomized trials or an FDA approval. Emerging-human means one to three small RCTs. Animal-only means real mechanism and animal data but no human efficacy. Preclinical or hype means mechanism plus marketing, and sometimes a hard safety problem, with no human efficacy at all.

Why do supplements outrank peptides on this particular ladder, when peptides win the search interest? Mostly a matter of how long each has been studied in people. Creatine and CoQ10 have decades of human trials; Urolithin A and the NAD+ precursors have cleared randomized controlled trials in the last few years; but the mitochondrial-derived peptides (MOTS-c, Humanin) were only discovered in the 2010s and have barely begun human testing, while the exercise-mimetic research chemicals (SLU-PP-332, 5-amino-1MQ) have never left the rodent stage. The mechanisms are genuinely exciting, which is why they dominate forums and vendor catalogs, but excitement about a mechanism is not the same as a finished human trial. This page deliberately ranks by the second thing, not the first.

How do these compounds actually work on the mitochondria?

Mitochondrial compounds do not all do the same thing: they hit different levers, from building new mitochondria (biogenesis) and clearing damaged ones (mitophagy), to refilling the NAD+ pool, feeding the electron transport chain, or activating the cellular energy sensor AMPK. Knowing which lever a compound pulls is the fastest way to see why two "energy" products are not interchangeable.

The cell has a handful of distinct mitochondrial controls, and the popular compounds map neatly onto them. Urolithin A triggers mitophagy, the recycling of worn-out mitochondria. NR and NMN feed the NAD+ salvage pathway, restoring the coenzyme that powers hundreds of reactions. CoQ10 is a direct cofactor in the electron transport chain that produces ATP. Creatine buffers ATP itself through the phosphocreatine shuttle. MOTS-c and SLU-PP-332 push biogenesis and AMPK, the exercise-mimetic levers. And the dangerous outliers, DNP and the experimental BAM15, work by uncoupling, deliberately wasting energy as heat, which is exactly why DNP is lethal.

This is why stacking logic only makes sense once you map the levers. Pairing an NAD+ precursor (salvage) with Urolithin A (mitophagy) targets two non-overlapping processes; pairing two NAD+ precursors mostly doubles cost. The mechanism map below shows which lever each compound pulls. For the cell-biology foundations of how peptides signal inside the body, see how peptides work.

The split between the two exercise-mimetic levers (biogenesis and AMPK) and the uncoupling lever is worth dwelling on, because it explains the single biggest safety divide in this category. Biogenesis and AMPK activation make the cell build more mitochondria and burn fuel more efficiently, which is the benign version of "boosting metabolism." Uncoupling does the opposite: it makes the mitochondria deliberately leaky so they waste energy as heat, which does burn fat but also strips the cell of its ability to regulate its own temperature. That is exactly why DNP, the classic uncoupler, has killed people through runaway hyperthermia, and why the "new DNP" research chemicals raise the same red flag. A compound that builds mitochondria and a compound that sabotages them can both be marketed as "energy," so the mechanism, not the marketing word, is what tells you which one is dangerous.

What does the ProtocolPlus peptide community track for mitochondrial health?

Among the four mitochondrial compounds our peptide community actually tracks, NAD+ leads at 32 percent (589 users), followed by MOTS-c at 30 percent (552), 5-amino-1MQ at 22 percent (405), and SLU-PP-332 at 16 percent (294), across a cohort of 1,840 users who logged an energy or mitochondrial goal. This is a usage signal from our own app, and it deliberately does not include the supplements that lead the evidence ladder, because those sit outside peptide tracking.

This is the honest tension worth naming. Our first-party data is a real moat, but it captures the peptide-and-research-chemical corner of this space, not the supplement boom (Urolithin A, NR, NMN, CoQ10, creatine) where the human evidence actually lives. So the community split below tells you what peptide-minded users reach for, while the evidence ladder above tells you what the data supports, and those two answers point in noticeably different directions here.

Read the split as behavior, not endorsement. NAD+ leads because the NAD+ story is the loudest in longevity, and MOTS-c is close behind as the flagship mitochondrial-derived peptide. But two of the four tracked compounds, 5-amino-1MQ and SLU-PP-332, are animal-only research chemicals, so nearly four in ten of these tracked picks have no human efficacy data at all. That gap is the whole reason this page leads with evidence, not usage.

Citation capsule. Among ~1,840 ProtocolPlus users who logged a cellular-energy or mitochondrial goal, the most-tracked compounds were NAD+ (32%, 589 users), MOTS-c (30%, 552), 5-amino-1MQ (22%, 405), and SLU-PP-332 (16%, 294). This is first-party usage data reflecting what the peptide community tracks, not a clinical efficacy ranking, and it excludes supplements (Urolithin A, NR, NMN, CoQ10, creatine) that lead the evidence ladder. Source: ProtocolPlus app data (goals/mitochondria.json), 2026.

NAD+, NMN, and NR: the engine of the boom

NAD+ is the coenzyme at the center of the mitochondrial story, and its oral precursors NR and NMN reliably raise blood NAD+ levels, but raising NAD+ is not the same as proven anti-aging, and the human hard-endpoint evidence is still modest. This is the single most important pathway to understand, because it drives most of the marketing in this category.

NAD+ powers hundreds of reactions, including the sirtuins tied to metabolic and mitochondrial health, and it declines with age, which is the premise of the entire NAD+ boom. You cannot usefully take NAD+ by mouth, so the practical approach is precursors. NR (nicotinamide riboside) has the cleanest safety and dose-response data, and NMN (nicotinamide mononucleotide) is the poster child of the boom with one notable efficacy trial. The honest framing is that both raise NAD+, but neither has shown the dramatic anti-aging outcomes the hype implies.

It helps to separate three distinct questions that the marketing usually blurs together. First, does the precursor raise blood NAD+? For NR and NMN the answer is a clear yes, and the dose-response is steep. Second, does the extra NAD+ reach the tissues you care about and change their function? Here the picture is muddier, because the 2021 NMN trial improved insulin sensitivity without a measurable rise in muscle NAD+, which suggests the link between a blood biomarker and a tissue outcome is not one-to-one. Third, does any of that translate into living longer or feeling more energetic in otherwise healthy people? That is the question the hype answers loudest and the data answers least, because the long, hard-endpoint human trials simply have not been run yet. Keeping those three questions separate is the single best defense against NAD+ marketing.

The numbers are real and worth anchoring. In 2019, a Conze and Brenner randomized trial reported that NR raised blood NAD+ by +22%, +51%, and +142% at 100 mg, 300 mg, and 1,000 mg per day with no excess adverse events (Conze, Brenner et al., Scientific Reports, 2019, retrieved 2026-06-19). In 2021, a Yoshino and Klein randomized trial in 25 prediabetic women found that NMN at 250 mg per day for 10 weeks improved muscle insulin sensitivity, though it did not measurably raise muscle NAD+ (Yoshino et al., Science, 2021;372:1224-29, retrieved 2026-06-19). NMN also rode a regulatory rollercoaster: the FDA delisted it as a supplement ingredient in 2022, then declared it lawful again in 2025 (NutraIngredients, 2025, retrieved 2026-06-19).

Citation capsule. NAD+ precursors raise blood NAD+ in humans: a 2019 RCT (Conze, Brenner; Scientific Reports) reported NR raised blood NAD+ by +22%, +51%, and +142% at 100, 300, and 1,000 mg/day with no excess adverse events; a 2021 RCT (Yoshino, Klein; Science) found NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity in 25 prediabetic women. Raising NAD+ is established; broad anti-aging benefit in healthy people is not. IV NAD+ remains unproven. Sources: Conze/Brenner 2019; Yoshino/Klein 2021.

The dose-response chart below shows the NR data. The caution that matters: injectable or IV NAD+ is largely unproven, with poorly characterized pharmacokinetics and unestablished cost and safety, so the loudest "NAD+ drip" marketing rests on the thinnest data. For the full mechanism, dosing, and the NAD+ versus precursor debate, see the NAD+ complete guide.

The evidence-led shortlist: each candidate, briefly

Here is each serious candidate in two to four sentences, in evidence order, with a link to go deeper where one exists. This page owns the "which one, and why" decision; the deep mechanism and dosing live on each compound's hub for the tracked peptides, while the leading supplements get a placement here.

Urolithin A (Mitopure)

The best-evidenced novel mitochondrial supplement. It activates mitophagy, the clearing of damaged mitochondria, and in a 2022 randomized trial (Cell Reports Medicine) it improved muscle strength by about 12 percent and endurance by about 17 percent versus placebo. It holds FDA GRAS status with a clean safety record; the effect sizes are modest, and the pivotal trials were funded by the ingredient company (Amazentis), which we disclose for transparency.

Creatine

The single strongest body of human evidence on this list. Creatine buffers ATP through the phosphocreatine shuttle and has a vast literature on strength and power, with emerging cognition data. It is cheap, very safe, and over-the-counter, which is exactly why it rarely appears on "exotic" mitochondrial lists despite outranking most of them on evidence.

CoQ10 / Ubiquinol

A direct electron-transport-chain cofactor with strong evidence in specific contexts: statin-associated muscle symptoms, heart failure (the Q-SYMBIO trial), and primary mitochondrial disease. For general "more energy" in healthy people the evidence is weaker, so frame it narrowly. It is very safe and widely available.

NR (Niagen)

The best-characterized NAD+ precursor for safety, with the cleanest dose-response data (blood NAD+ up to +142% at 1,000 mg in the 2019 RCT) and FDA-accepted ingredient status. The catch is that raising NAD+ is established while downstream clinical benefit in healthy people is still thin. Like Urolithin A, its pivotal work was ingredient-company funded (ChromaDex), which we disclose.

NMN

The poster child of the NAD+ boom, with one notable efficacy trial (the 2021 Science insulin-sensitivity RCT in prediabetic women) and a dramatic regulatory saga: delisted by the FDA in 2022, declared lawful again in 2025. It raises NAD+ like NR but has thinner safety characterization. Full context: the NAD+ guide.

Elamipretide (SS-31)

The pharma frontier and the only FDA-approved mitochondria-targeted drug. It stabilizes cardiolipin to improve electron-transport efficiency, and in September 2025 it earned FDA accelerated approval (FORZINITY) for Barth syndrome, an ultra-rare genetic disease, based on improved knee-extensor strength (Stealth BioTherapeutics / FDA, 2025, retrieved 2026-06-19). It is prescription-only and rare-disease only, not a general energy supplement; broader mitochondrial-myopathy results have been mixed.

MOTS-c (one to watch)

The flagship mitochondrial-derived peptide our community tracks, an AMPK-activating exercise-mimetic with strong animal data on biogenesis and insulin sensitivity, and a human trial now recruiting. There is no completed human efficacy RCT yet, so it is a credible "one to watch," not a proven pick. Full guide: the MOTS-c complete guide.

Humanin (one to watch)

A second mitochondrial-derived peptide with cytoprotective and metabolic signaling in animal and in-vitro work, often discussed alongside MOTS-c in longevity circles. Like MOTS-c, it has no human efficacy data and belongs in the "watch the trials" bucket, not a current recommendation.

Supporting cast: Spermidine, Acetyl-L-Carnitine, Alpha-Lipoic Acid

Three real but indirect supplements. Spermidine induces autophagy and has small human trials plus longevity epidemiology; acetyl-L-carnitine shuttles fatty acids into mitochondria with modest energy and cognition data; alpha-lipoic acid is a mitochondrial cofactor and antioxidant best evidenced in diabetic neuropathy. All are safe and over-the-counter, with effects that are genuine but modest.

Flagged: SLU-PP-332 and 5-Amino-1MQ

Two animal-only research chemicals our community tracks. SLU-PP-332 is an ERR agonist that drove large endurance gains in untrained mice via biogenesis; 5-amino-1MQ is an oral NNMT inhibitor that raised NAD+ and curbed fat gain in obese mice. Neither has any human efficacy or safety data, so any human claim is extrapolation from rodents. Guides: SLU-PP-332 guide and 5-amino-1MQ guide.

Do not use: Cardarine, DNP, IV NAD+, methylene blue

Cardarine (GW-501516) is WADA-banned and caused multi-organ cancers in rats, so no responsible list recommends it (USADA, GW1516, retrieved 2026-06-19). DNP is an uncoupler the FDA banned in 1938 after repeated fatalities from hyperthermia, included here only as a cautionary tale. IV NAD+ is unproven with unestablished safety and cost, and the methylene blue "ATP and oxygen" energy claims are unverified vendor marketing, not clinical data.

Which mitochondrial compound fits your situation?

The right pick depends on a few filters you can answer in a sentence: do you want proven human evidence or are you open to experimental mechanisms, do you want oral or are needles fine, and how much unproven risk you will accept. The matrix below sets the leading candidates against the dimensions that actually decide it.

This table is the editorial "why" behind the evidence ladder, not a usage chart. The selector quiz at the top runs the same logic interactively: choosing evidence-first pushes the supplements and the approved drug to the top, while choosing open to experimental surfaces the animal-stage peptides. Use it to narrow, then read the evidence column honestly, because the highest-evidence options here are mostly the least hyped.

A practical way to read the table: start from your actual situation rather than the most exciting molecule. If you are healthy and want a low-risk, well-proven base, the answer is almost boring on purpose, creatine plus a sensible diet, with Urolithin A as the best-evidenced add-on if you want to target mitophagy specifically. If you have a clinical reason, such as statin-associated muscle symptoms or a diagnosed mitochondrial condition, CoQ10 has the narrowest but strongest indication, and elamipretide is a clinician-led prescription path, not a self-directed one. If you are specifically chasing the NAD+ story, NR is the safer-characterized precursor to start with over NMN. And if you are drawn to the peptides, the honest framing is that you are an early adopter of an unproven mechanism, which is a legitimate choice to make knowingly, but not the same as picking something proven.

What the community tracks is not what is proven best

Treat the community-tracking split as a behavior signal shaped by hype, marketing, and what is buyable as a peptide, not as evidence of what works best or safest. The clearest tell is that nearly four in ten tracked picks here are animal-only research chemicals, while the compounds with the strongest human evidence barely appear because they are sold as ordinary supplements.

Three honest framings sit on top of every number on this page. First, the best human evidence is for supplements, not peptides: Urolithin A, creatine, CoQ10, and NR each have human trials, while the tracked mitochondrial peptides (MOTS-c, Humanin) are still animal-stage. Second, raising NAD+ is not proven anti-aging: NR and NMN reliably lift blood NAD+, but lifting a biomarker is not the same as living longer or feeling more energetic, and IV NAD+ specifically is unproven. Third, animal data is not human data, and several popular picks (SLU-PP-332, 5-amino-1MQ) have only ever been tested in rodents, while Cardarine and DNP carry hard safety dealbreakers. For grounded expectations and how to read transformation claims, see peptides before and after, and before sourcing anything, how to vet peptide quality.

Our take: The most useful way to read this page is as two layers. The community donut tells you what peptide-minded people are tracking; the evidence ladder tells you what the data supports. Here those two layers genuinely disagree, and when they do, the honest move is to trust the evidence and treat the hype as a map of what is being marketed, not what is proven.

The market boom, in honest numbers

The longevity-supplement market is large and growing fast, which explains the wall of marketing around these compounds, but market size is a measure of demand and hype, not of proven benefit. It is worth seeing the scale so you can read the marketing with the right skepticism.

By analyst estimates, the longevity-supplements market is roughly $8.75 billion in 2025, projected to reach about $14.29 billion by 2030 (The Business Research Company, 2025, retrieved 2026-06-19), and the NAD+ precursor segment alone is estimated at about $350 million in 2025, growing toward $779 million by 2035 (Future Market Insights, 2025, retrieved 2026-06-19). These are proprietary analyst estimates presented as ranges, not hard public statistics. The brand anchors are familiar: ChromaDex and Tru Niagen for NR, Amazentis and Timeline for Urolithin A, and Stealth BioTherapeutics' FORZINITY as the legitimizing pharma proof point.

The honest counter-narrative matters more than the numbers. Animal lifespan and fat-loss results rarely translate into matching human efficacy; the NMN regulatory turbulence shows how unsettled even the boom's leaders are; and the most viral claims (methylene blue's "blue tongue" energy moment, the NAD+ drip) rest on the least evidence. For the full trend and market story, see the pillar: the mitochondrial performance supplement boom. And if your real goal is performance rather than general cellular health, the on-intent siblings are best peptides for endurance and best peptides for VO2max.

Who should be cautious, and who should not use these

These compounds are not all created equal on safety, and the research-grade ones are not for anyone outside a clinician's oversight. The supplements are mostly low-risk; the peptides and research chemicals add unknown-risk on top, and a couple are outright dangerous.

A few hard lines worth stating. The well-evidenced supplements (Urolithin A, creatine, CoQ10, NR) are generally well tolerated, but anyone pregnant, breastfeeding, on multiple medications, or managing a chronic condition should still clear them with a clinician, and methylene blue specifically carries serotonin-syndrome interaction risk with antidepressants. Elamipretide is a prescription drug for a diagnosed rare disease, not a self-directed option. For the animal-only research chemicals (MOTS-c, Humanin, SLU-PP-332, 5-amino-1MQ), the responsible answer is simpler: there is no validated safe-use protocol, so they belong in a trial or under a clinician, not a self-directed cycle. And Cardarine and DNP should not be used at all. None of this page is a substitute for that conversation.

Frequently Asked Questions

The bottom line

If you came here for the single best peptide for mitochondrial health, the honest answer rearranges the question. The compounds with the strongest human evidence are not peptides at all, they are supplements: Urolithin A, creatine, CoQ10, and the NAD+ precursor NR, with NMN close behind. The only FDA-approved mitochondria-targeted drug, elamipretide, is a prescription treatment for one rare disease, not a general booster. The peptides our community is most excited about, MOTS-c and Humanin, are genuinely promising but still animal-stage "ones to watch."

The compounds to be most skeptical of are the ones whose hype outruns their evidence: SLU-PP-332 and 5-amino-1MQ have only rodent data, and Cardarine and DNP carry hard safety dealbreakers. The selector at the top narrows the field to your constraints, evidence-first or experimental, oral or injectable, but the final call belongs with a clinician who knows your health history. From here, the natural next reads are the trend pillar on the mitochondrial performance supplement boom, the NAD+ guide, and the MOTS-c guide.

Sources

• Singh A, D'Amico D, Andreux PA, et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 2022. Retrieved 2026-06-19. https://www.sciencedirect.com/science/article/pii/S2666379122001586
• Conze D, Brenner C, Kruger CL. "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults." Scientific Reports, 2019. Retrieved 2026-06-19. https://www.nature.com/articles/s41598-019-46120-z
• Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021;372:1224-1229. Retrieved 2026-06-19. https://www.science.org/doi/10.1126/science.abe9985
• U.S. Food & Drug Administration. "GRAS Notice No. 791 (Urolithin A)." Retrieved 2026-06-19. https://www.fda.gov/media/132889/download
• Stealth BioTherapeutics. "FDA Accelerated Approval of FORZINITY (elamipretide HCl), the First Therapy for Barth Syndrome." 2025. Retrieved 2026-06-19. https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome-302562058.html
• NutraIngredients. "FDA declares NMN lawful in dietary supplements." September 30, 2025. Retrieved 2026-06-19. https://www.nutraingredients.com/Article/2025/09/30/fda-declares-nmn-lawful-in-dietary-supplements/
• U.S. Anti-Doping Agency (USADA). "What should athletes know about GW1516 (Cardarine)?" Retrieved 2026-06-19. https://www.usada.org/spirit-of-sport/what-should-athletes-know-gw1516/
• The Business Research Company. "Longevity Supplements Global Market Report." 2025. Analyst estimate. Retrieved 2026-06-19. https://www.thebusinessresearchcompany.com/report/longevity-supplements-global-market-report
• Future Market Insights. "NAD+ Precursor Market." 2025. Analyst estimate. Retrieved 2026-06-19. https://www.futuremarketinsights.com/reports/nad-precursor-market
• ProtocolPlus. "Community goal-usage data: cellular energy and mitochondrial health" (goals/mitochondria.json). First-party app data, 2026. n ≈ 1,840 users; tracked subset only (excludes supplements). Usage signal, not a clinical efficacy ranking.